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Abstract
Background: Overuse of anti-cancer therapy is an important quality-of-care issue. An aggressive approach to
treatment can have negative effects on quality of life and cost, but its effect on survival is not well-defined.
Methods: Using the Surveillance, Epidemiology, and End Results-Medicare database, we identified 7,879 Medicare-
enrolled patients aged 65 or older who died after having survived at least 3 months after diagnosis of advanced
non-small cell lung cancer (NSCLC) between 1991 and 1999. We used Cox proportional hazards regression analysis,
propensity scores, and instrumental variable analysis (IVA) to compare survival among patients who never received
chemotherapy (n = 4,345), those who received standard chemotherapy but not within two weeks prior to death (n
= 3,235), and those who were still receiving chemotherapy within 14 days of death (n = 299). Geographic variation
in the application of chemotherapy was used as the instrument for IVA.
Results: Receipt of chemotherapy was associated with a 2-month improvement in overall survival. However, based
on three different statistical approaches, no additional survival benefit was evident from continuing chemotherapy
within 14 days of death. Moreover, patients receiving chemotherapy near the end of life were much less likely to
enter hospice (81% versus 51% with no chemotherapy and 52% with standard chemotherapy, P < 0.001), or were
more likely to be admitted within only 3 days of death.
Conclusions: Continuing chemotherapy for advanced NSCLC until very near death is associated with a decreased
likelihood of receiving hospice care but not prolonged survival. Oncologists should strive to discontinue
chemotherapy as death approaches and encourage patients to enroll in hospice for better end-of-life palliative
care.
Background
The paucity of information regarding cancer prognosis,
treatment options, and the possible consequences of
treatment make it difficult for terminally ill patients to
make appropriate end-of-life treatment choices,[1-4]
despite a growing awareness of the importance of high
quality end-of-life care. We have previously shown that
the aggressive use of chemotherapy in patients who are
close to death has been increasing over time [5]. In fact,
although an aggressive approach to treatment during
the last week of life is linked to psychological and physi-
cal distress for advanced cancer patients,[6,7] little infor-
mation is available about the clinical effects of such
treatment [8]. A systematic review of the literature from
the past two decades found that patients would choose
chemotherapy near death for much smaller expected
benefits in outcome than would health care providers,
[4] indicating a skepticism on the part of physicians for
this kind of care. Other studies have also shown that
chemotherapy is used near death irrespective of the can-
cer’s responsiveness to therapy [9,10]. Such treatment
has been associated with potentially negative effects,
including higher numbers of emergency room (ER) vis-
its, hospitalizations, and admissions to the intensive care
unit (ICU), and less hospice service [5,11]. These results
beg the question of whether aggressive care leads to
improved outcomes. To address this issue, we evaluated
the effect of an aggressive approach to care, defined as
continuation of chemotherapy within two weeks of
death, on survival in a cohort of patients with metastatic
non-small cell lung cancer.
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Definition of standard chemotherapy and aggressive-
approach chemotherapy
The receipt of chemotherapy for each patient was identi-
fied from billing claims [12]. For the purpose of this
study, we defined ‘no chemotherapy’ patients as those
who never received chemotherapy after their cancer diag-
nosis, ‘standard chemotherapy’ recipients as those who
did receive chemotherapy for their cancer but not during
the 14 days prior to death, and ‘aggressive-approach che-
motherapy’ recipients as those who were still receiving
chemotherapy within 14 days of death [13].
Data sources and identification of the study cohort
The study was approved by the Dana-Farber/Partners
Cancer Care Institutional Review Board. The data for
this study were extracted from the linked Surveillance,
Epidemiology, and End Results (SEER)-Medicare data-
base, compiled by the National Cancer Institute. Eleven
tumor registries participated in the SEER program dur-
ing the period of study. Approximately 97% of all the
cancer cases that occur in the regions encompassed by
the registries are captured,[14] covering a representative
sample of approximately 14% of the United States popu-
lation [15,16]. For each patient, SEER registries collect
data on age, gender, race/ethnicity, cancer site, stage,
histology, date of cancer diagnosis, and date of death.
Data from the 2000 Census, such as the median and per
capita income and wealth, have been merged with the
registry data. Claims for inpatient and outpatient care,
physician and laboratory services, and hospice care were
retrieved from the Medicare database.
The potentially eligible study cohort included 15,391
patients who were 65 years or older, were diagnosed
with metastatic non-small cell lung cancer, and died of
their disease between 1991 and 1999. This cohort did
not include patients who were enrolled in Medicare for
end-stage renal failure or disability instead of older age,
and those whose cancer diagnoses were detected from
autopsy or death certificates. Patients who did not have
continuous Medicare enrolment (Part A and Part B) or
who were enrolled in a health maintenance organization
(HMO) at any time in the year prior to death were also
excluded. When estimating survival among three treat-
ment groups in the potentially eligible study cohort,
aggressive-approach chemotherapy recipients died very
quickly compared to standard chemotherapy recipients
(P < 0.05, data not shown), suggesting the possibility of
high proportion of patients with rapid disease progres-
sion in the aggressive-approach chemotherapy group or
a negative effect of such care. To eliminate the first
case, we excluded patients who died within three
months from their diagnosis (n = 7,512). This is consis-
tent with the eligibility criteria for most clinical
protocols that examine the effects of chemotherapy,
which usually require patients to have at least a three-
month prognosis. Thus, a total of 7,879 patients were
included in the final cohort. The excluded cohorts had a
tendency not to receive any chemotherapy compared
with the study cohort who survived at least 3 months
(15% versus (vs.) 45%), while the proportion receiving
chemotherapy near the end of life were the same
between the two groups (4% vs. 4%), suggesting the
choice of aggressive-approach chemotherapy was not
influenced by patients’ prognoses. We also confirmed
that the inclusion of the excluded cohort did not change
the results in sensitivity analyses. These findings support
the fact that the study cohort was valid and aggressive-
approach chemotherapy recipients were not just those
with poor prognosis.
Statistical analysis
1) Definition and classification of explanatory variables
Patients were categorized into three treatment groups:
no chemotherapy, standard chemotherapy, or an aggres-
sive approach to chemotherapy. Control variables
included patient age at diagnosis, gender, race/ethnicity
(non-Hispanic white, non-Hispanic black, Hispanic, or
other), geographic region (Northeast, South, Midwest, or
West), urban residence (densely-settled area with more
than 2,500 residences-yes or no), whether they were
treated at a teaching hospital at any time between can-
cer diagnosis and death (yes or no), and year of death.
A Charlson comorbidity index (0, 1, or 2 or more) was
calculated by using the algorithm described elsewhere
[17-19]. Socioeconomic quintiles were developed follow-
ing the method described by Bach et al. [20]; Only
eighty-six patients for whom no income data were avail-
able were grouped in the lowest quintile of socioeco-
nomic status, and exclusion of their data did not change
the results in sensitivity analyses. Based on billing infor-
mation, patients were divided into three groups accord-
ing to the length of hospice care (none, three or fewer
days, or four or more days).
2) Analytical approach
Unadjusted comparison Descriptive statistical analyses
to assess baseline sociodemographic and disease charac-
teristics among patients in the three treatment groups
were performed using Chi-square tests for categorical
variables and Wilcoxon rank-sum tests for continuous
variables, with the Kruskal-Wallis test used for overall
comparisons. Overall survival (OS) was calculated using
the Kaplan-Meier method,[21] and a log-rank test [22]
was used for group comparisons.
Adjusted comparison-1: multiple Cox regression ana-
lysis We used a Cox proportional hazards regression
model to compare relative risks and 95% confidence
intervals (95%CIs) for mortality in the three treatment
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patient age, gender, the Charlson comorbidity index,
race/ethnicity, geographic region, urban residence,
socioeconomic status, teaching hospital, and year of
death. Any variables that were significantly associated
with the receipt of chemotherapy in the univariate ana-
lyses were considered for inclusion in the model. Signifi-
cant variables associated with survival were identified
through stepwise selection, and interaction terms that
revealed significant effect modification (i.e. the interac-
tion term with treatment group was significant) were
further investigated.
Adjusted comparison-2: propensity score analysis Pro-
pensity score (PS) approaches have been proposed as a
less parametric alternative when there are large observed
differences between treatment groups. The PS, intro-
duced by Rosenbaum and Rubin in 1983,[23] is the con-
ditional probability of assignment to a certain treatment
procedure, given sociodemographic and disease charac-
teristics. PS methods thus permit control for all
observed confounding factors that might influence both
choice of treatment and outcome using a single compo-
site measure, without requiring specification of the rela-
tionships between the control variables and outcome,
which differs from a Cox proportional hazards regres-
sion model.
We first calculated the propensity for receiving che-
motherapy with a logistic regression model, which
includes all the control variables. We examined the
overlap in PS among patients who received chemother-
apy and those who did not to ensure the suitability of
comparing treatment outcome between the two groups.
We then stratified the sample of patients into five pro-
pensity strata. Within each stratum, we estimated survi-
val separately using a Cox proportional hazards
regression model. A multivariable Cox regression adjust-
ment using PS as a continuous variable was also
performed.
The same process was repeated for patients who ever
received chemotherapy: the propensity for undergoing
an aggressive approach to chemotherapy was calculated,
patients were divided into five propensity strata, and
survival was estimated using both a Cox proportional
hazards regression model within each stratum in which
confounding factors were substantially reduced [23,24]
and a multivariable Cox regression adjustment using PS
as a continuous variable.
Adjusted comparison-3: instrumental variable analy-
sis The two preceding statistical tools do not directly
consider unobserved factors that may be unrelated to
observed variables, but may nevertheless affect treat-
ment choices and/or their outcomes. The instrumental
variable analysis (IVA) method, first developed in the
field of econometrics [25] and applied to the field of
health care research since the mid-1990s,[12,26-29] per-
mits the consideration of not only observed factors, but
also unobserved factors that might influence outcomes.
The instrumental variable (IV) in an IVA should inde-
pendently influence patients’ or physicians’ treatment
choice, but should not be associated with outcomes. On
the basis of findings from several published studies,
[30,31] we used treatment rates within Health Care Ser-
vice Areas (HCSAs),[32] a classification of geographic
areas based on observed referral patterns for tertiary
care, and stratified by the availability of health care
resources, as the IV. To confirm the assumption of this
analysis, we included the IVs in a Cox proportional
hazards regression model to determine that it would not
predict survival independently. Also, we confirmed that
sociodemographic and disease characteristics across IVs
are more similar than when we compared those charac-
teristics among the three treatment groups.
First, we calculated the numbers of elderly patients
receiving chemotherapy for advanced lung cancer in
each HCSA. HCSAs with five or fewer patients treated
with or without chemotherapy were excluded. The
remaining HCSAs were divided into quintiles based on
the proportion of patients receiving chemotherapy. We
then calculated the IV estimates for the “marginal
patient population,” which is defined as patients who
would receive chemotherapy if they lived in a HCSA
with a high chemotherapy utilization rate but not if they
lived in a HCSA with low chemotherapy utilization rate
[33]. A non-parametric two-stage least squares model
was used to predict treatment in the first stage based on
IV quintiles. These models also controlled for patient
age, race/ethnicity, gender, socioeconomic status, Charl-
son comorbidity index, and the year of death. Among
those who ever received chemotherapy, we took the
same approach from the perspective of more and less
aggressive-approach chemotherapy utilization and esti-
mated the clinical effect of receiving chemotherapy
within 14 days of death for the marginal patient
population.
All tests were two-tailed, and P-values less than 0.05
were considered significant. All analyses were performed
using SAS software, version 9.1 (SAS Institute, Cary,
NC).
Results
Patient characteristics
Table 1 summarizes the characteristics of the study
population. Of the 7,879 patients, 3,534 patients (44.9%)
had ever received chemotherapy, and 299 (8.5%) of
t h o s ep a t i e n t sw e r es t i l lr e c e iving chemotherapy within
14 days of death.
Several factors differed between patients who received
chemotherapy and those who did not. Recipients of
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Page 3 of 11Table 1 Characteristics of 7,879 patients with metastatic non-small cell lung cancer by receipt of chemotherapy
Variables No
chemotherapy
(n = 4,345)
Standard
chemotherapy
(n = 3,235)
Aggressive
-approach
chemotherapy
(n = 299)
P-value
3
groups
No chemo-
therapy vs.
Chemo- therapy*
Standard chemotherapy vs.
Aggressive -approach
chemotherapy
Age at diagnosis,
years
Median
[IQR]
73.0 [69.0-78.0] 71.0 [68.0-74.0] 70.0 [67.0-74.0] < 0.001 < 0.001 0.36
Gender, n (%) Female 1,938 (44.6) 1,291 (39.9) 108 (36.1) < 0.001 < 0.001 0.20
Male 2,407 (55.4) 1,944 (60.1) 191 (63.9)
Charlson comorbidity
index, n (%)
0 3,123 (71.9) 2,401 (74.2) 226 (75.6) < 0.001 < 0.001 0.06
1 773 (17.8) 576 (17.8) 60 (20.1)
2 ≤ 449 (10.3) 258 (8.0) 13 (4.4)
Race/Ethnicity, n (%) non-
Hispanic
white
3,551 (81.7) 2,711 (83.8) 254 (85.0) 0.01 0.01 0.22
non-
Hispanic
black
425 (9.8) 248 (7.7) 21 (7.0)
Hispanic
or other
369 (8.5) 276 (8.5) 24 (8.0)
Region of tumor
registries, n (%)
Northeast 672 (15.5) 555 (17.2) 51 (17.1) < 0.01 < 0.01 0.06
South 228 (5.3) 194 (6.0) 28 (9.4)
Midwest 1,426 (32.8) 1,101 (34.0) 86 (28.8)
West 2019 (46.5) 1385 (42.8) 134 (44.8)
Urban residence, n
(%)
Yes 3,928 (90.4) 2,973 (91.9) 284 (95.0) < 0.01 < 0.01 0.06
No 417 (9.6) 262 (8.1) 15 (5.0)
Socioeconomic status,
n (%)
Highest
quintile
763 (17.6) 682 (21.1) 71 (23.8) < 0.001 < 0.001 0.85
Fourth
quintile
793 (18.3) 673 (20.8) 63 (21.1)
Third
quintile
866 (19.9) 688 (21.3) 59 (19.7)
Second
quintile
849 (19.5) 635 (19.6) 56 (18.7)
Lowest
quintile
1,074 (24.7) 557 (17.2) 50 (16.7)
Median income Median
[IQR]
38,154 [29-152] 41,205 [32-757] 43,564 [32-179] < 0.001 < 0.001 0.28
Teaching hospital, n
(%)
Yes 2,110 (48.6) 1,868 (57.7) 163 (54.5) < 0.001 < 0.001 0.28
No 2,235 (51.4) 1,367 (42.3) 136 (45.5)
Year of death, n (%) 1991 365 (8.4) 206 (6.4) 18 (6.0) < 0.001 < 0.001 0.02
1992 576 (13.3) 299 (9.2) 22 (7.4)
1993 567 (13.1) 340 (10.5) 15 (5.0)
1994 581 (13.4) 339 (10.5) 33 (11.0)
1995 518 (11.9) 372 (11.5) 33 (11.0)
1996 490 (11.3) 424 (13.1) 32 (10.7)
1997 442 (10.2) 413 (12.8) 46 (15.4)
1998 421 (9.7) 421 (13.0) 52 (17.4)
1999 385 (8.9) 421 (13.0) 48 (16.1)
Death in the hospital,
n (%)
Yes 774 (17.8) 812 (25.1) 152 (50.8) < 0.001 < 0.001 < 0.001
No 3,571 (82.2) 2,423 (74.9) 147 (49.2)
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chemotherapy, were younger, more likely to be male,
and less likely to have comorbidity compared with non-
recipients. The chemotherapy group had more non-His-
panic white patients and those who were more likely to
reside in the Northeast or South, in urban areas, be
admitted to teaching hospitals, have higher socioeco-
nomic status, and to have died in more recent years
compared with the no chemotherapy group. Among
patients who ever received chemotherapy, recipients of
chemotherapy near death had less comorbidity and
tended to have died in more recent years, were more
likely to reside in the South, were less likely to reside in
the Midwest, and more often resided in urban areas
compared to standard chemotherapy recipients.
Unadjusted outcomes
Deaths in the hospital, ER visits and ICU admissions
were more common in patients who received standard
chemotherapy compared to patients who did not receive
chemotherapy, and each of these outcomes occurred
even more frequently in recipients of chemotherapy
near death (Table 1). Over 40% of patients in the group
without chemotherapy or those in the standard che-
motherapy group had hospice stays of four or more
days, compared with only 11% of those in the aggres-
sive-approach chemotherapy group; in fact, over 80% of
those receiving chemotherapy near death received no
h o s p i c ec a r e( T a b l e1 ) .T h eu n a d j u s t e ds u r v i v a lr a t e s
among the three groups by receipt of chemotherapy are
shown in Figure 1. The median survival of patients who
received no chemotherapy, standard chemotherapy, and
aggressive-approach chemotherapy were 6 months, 8
months, and 8 months, respectively. Survival of these
three groups at 1 year was 18.6% for the group with no
chemotherapy, 27.2% for the standard chemotherapy
group, and 28.6% for the aggressive-approach che-
motherapy group, respectively (3 groups, P < 0.001; no
chemotherapy vs. any chemotherapy, P < 0.001; standard
chemotherapy vs. aggressive-approach chemotherapy, P
= 0.83).
Adjusted outcomes
1) Results from Cox model
In the Cox regression analysis, adjusted hazard ratios
(HR) of patients with standard chemotherapy or che-
motherapy near death were significantly lower compared
to patients who received no chemotherapy, overlapping
confidence intervals between recipients of standard and
aggressive-approach chemotherapy approaches (standard
Table 1 Characteristics of 7,879 patients with metastatic non-small cell lung cancer by receipt of chemotherapy
(Continued)
ICU admission within
1 month of death, n
(%)
Yes 187 (4.3) 213 (6.6) 37 (12.4) < 0.001 < 0.001 < 0.001
No 4,158 (95.7) 3,022 (93.4) 262 (87.6)
More than 1 ER visit
within 1 month of
death, n (%)
Yes 870 (20.0) 857 (26.5) 104 (34.8) < 0.001 < 0.001 < 0.01
No 3,475 (80.0) 2,378 (73.5) 195 (65.2)
Hospice admission, n
(%)
None 2,208 (50.8) 1,668 (51.6) 241 (80.6) < 0.001 < 0.001 < 0.001
Three or
fewer
days
156 (3.6) 198 (6.1) 25 (8.4)
Four or
more
days
1,981 (45.6) 1,369 (42.3) 33 (11.0)
Abbreviation: vs., versus; IQR, interquartile range; ICU, intensive care unit; ER, emergency room.
*Chemotherapy includes standard chemotherapy or aggressive-approach chemotherapy
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Figure 1 Unadjusted survival among for metastatic non-small
cell lung cancer patients by receipt of chemotherapy. Three
lines indicate patients who never received chemotherapy (solid
line), those who received standard chemotherapy (dashed line), and
those who received an aggressive chemotherapy approach
continued to within 14 days of death (thick dashed line).
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Page 5 of 11chemotherapy, HR = 0.80, 95%CI 0.76, 0.83, P < 0.001;
aggressive-approach chemotherapy, HR = 0.82, 95%CI
0.72, 0.92, P < 0.001, Table 2). When making standard
chemotherapy the reference group (data not shown), no
chemotherapy was associated with worse survival (HR =
1.26, 95%CI 1.20, 1.32, P < 0.001) and chemotherapy
near the end of life did not have any impact on survival
compared to standard chemotherapy (HR = 1.03, 95%CI
0.91, 1.16, P = 0.66). Older age at diagnosis, male gen-
der, worse comorbidity index, and residence in the West
were associated with worse survival. Race/ethnicity,
urban residence, socioeconomic status, and treatment in
teaching hospitals were not related to survival. Signifi-
cantly improved survival was evident in 1998 and 1999
relative to 1991 (Table 2).
2) Results from propensity score analyses
Care in a teaching hospital was more likely to be pro-
vided to chemotherapy recipients compared to non-reci-
pients, whereas among patients who ever received
chemotherapy, those in teaching hospitals were less
likely to receive chemotherapy near death. Prognostic
factors were well balanced across the propensity strata.
There was considerable overlap in the PSs of che-
motherapy recipients compared to non-recipients. Mean
PS to receive chemotherapy was 0.50 (95%CI 0.23, 0.77)
in the chemotherapy group and was 0.41 in the group
with no chemotherapy (95%CI 0.12, 0.70). Standard che-
motherapy recipients had a mean PS to receive aggres-
sive-approach chemotherapy of 0.08 (95%CI 0.02, 0.15),
while those with aggressive-approach chemotherapy had
a mean PS of 0.10 (95%CI 0.03, 0.16).
The Cox regression model using the PS is shown in
Table 3. The Cox regression adjustment using the PS as
a continuous variable showed that the HR for che-
motherapy recipients was 0.76 (95%CI 0.71, 0.82, P <
0.001), and those stratified by the PS quintiles found
that it ranged from 0.73 to 0.85 across propensity strata
(all P < 0.01). Of those who received any chemotherapy
(Table 4), the HR for aggressive-approach chemotherapy
recipients was 1.21 (95%CI 1.00, 1.48, P = 0.05) from
the Cox regression adjustment using the PS as a contin-
uous variable. There appeared to be a trend of
Table 2 Factors significantly associated with survival in multiple Cox regression analysis
Variables HR (95%CI) P-value
Receipt of chemotherapy No chemotherapy 1.00 - -
Standard chemotherapy 0.80 (0.76, 0.83) < 0.001
Aggressive-approach chemotherapy 0.82 (0.72, 0.92) < 0.001
Age at diagnosis 65 1.00 - -
Each increasing year 1.01 (1.00, 1.01) < 0.001
Gender Female 1.00 - -
Male 1.09 (1.05, 1.14) < 0.001
Charlson comorbidity index 0 1.00 - -
1 1.16 (1.09, 1.23) < 0.001
2 ≤ 1.28 (1.18, 1.38) < 0.001
Region of tumor registries Northeast 1.00 - -
South - - n.s.
Midwest - - n.s.
West 1.08 (1.03, 1.13) < 0.001
Socioeconomic status Lowest quintile 1.00 - -
Each increasing quintile - - n.s.
Teaching hospital No 1.00 - -
Yes - - n.s.
Year of death 1991 1.00 - -
1992 1.11 (1.04, 1.19) < 0.01
1993 - - n.s.
1994 - - n.s.
1995 - - n.s.
1996 - - n.s.
1997 - - n.s.
1998 0.91 (0.84, 0.97) < 0.01
1999 0.89 (0.82, 0.96) < 0.01
Abbreviation: HR, hazard ratio; CI, confidence interval; n.s., not significant.
NOTE: Stepwise selection was used. Race/ethnicity, and living in urban region were not found to be significant predictors of survival in univariate analysis (P-
value > 0.20).
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chemotherapy near death, ranging from 1.32 to 0.85,
and the interaction between receipt of an aggressive
approach to chemotherapy and propensity quintiles was
marginally significant (P = 0.07).
3) Results from instrumental variable analysis
We report selected baseline characteristics of patients
according to geographic quintiles of chemotherapy utiliza-
tion in Table 5. Thirty-one percent of the 1,492 patients in
the lowest quintile received chemotherapy, and 52% of the
2,139 patients in the highest quintile received chemother-
apy. Patients were similar in most observed characteristics
including age, gender, race/ethnicity, and socioeconomic
status. In addition, the Cox proportional hazards regres-
sion model showed that the IV was not an independent
predictor of survival supporting its use as an instrumental
variable. Using quintile of chemotherapy utilization as an
instrumental variable, we did not observe an association
between use of chemotherapy and survival for marginal
patients at 1 year (6.7 percentage points; 95%CI -6.6,
19.9%; P = 0.32) or at 2 years (1.7 percentage points; 95%
CI -5.9, 9.3%; P = 0.66).
Similarly, in model 2, we compared survival across
quintiles based on the rate of chemotherapy utilization
Table 3 Propensity score analysis results 1: Survival impact across quintiles based on the propensity to receive
chemotherapy among patients with metastatic non-small cell lung cancer, who survived at least 3 months after their
cancer diagnosis (n = 7,879)
Analysis Variables HR (95%CI) P-value
Stratified analysis
Lowest quintile of PS* No chemotherapy 1.00 - -
Chemotherapy 0.82 (0.73, 0.93) < 0.01
Second quintile of PS No chemotherapy 1.00 - -
Chemotherapy 0.77 (0.69, 0.85) < 0.001
Third quintile of PS No chemotherapy 1.00 - -
Chemotherapy 0.81 (0.74, 0.90) < 0.001
Fourth quintile of PS No chemotherapy 1.00 - -
Chemotherapy 0.85 (0.77, 0.93) < 0.01
Highest quintile of PS
† No chemotherapy 1.00 - -
Chemotherapy 0.73 (0.66, 0.81) < 0.001
Multiple Cox regression adjustment using the PS No chemotherapy 1.00 - -
Chemotherapy 0.76 (0.71, 0.82) < 0.001
Abbreviation: HR, hazard ratio; CI, confidence interval; PS, propensity score.
* Patients are least likely to receive “chemotherapy.”
† Patients are most likely to receive “chemotherapy.”
Table 4 Propensity score analysis results 2: Survival impact across quintiles based on the propensity to receive
aggressive-approach chemotherapy within 14 days of death among chemotherapy recipients with metastatic non-
small cell lung cancer, who survived at least 3 months after their cancer diagnosis (n = 3,534)
Analysis Variables HR (95%CI) P-value
Stratified analysis
Lowest quintile of PS* Standard chemotherapy 1.00 - -
Aggressive-approach chemotherapy 1.32 (0.90, 1.92) 0.15
Second quintile of PS Standard chemotherapy 1.00 - -
Aggressive-approach chemotherapy 1.30 (0.98, 1.72) 0.07
Third quintile of PS Standard chemotherapy 1.00 - -
Aggressive-approach chemotherapy 1.22 (0.81, 1.84) 0.35
Fourth quintile of PS Standard chemotherapy 1.00 - -
Aggressive-approach chemotherapy 1.21 (0.94, 1.56) 0.14
Highest quintile of PS
† Standard chemotherapy 1.00 - -
Aggressive-approach chemotherapy 0.85 (0.68, 1.07) 0.16
Multiple Cox regression adjustment using the PS Standard chemotherapy 1.00 - -
Aggressive-approach chemotherapy 1.21 (1.00, 1.48) 0.05
Abbreviation: HR, hazard ratio; CI, confidence interval; PS, propensity score.
* Patients are least likely to receive “aggressive-approach chemotherapy within 14 days of death.”
† Patients are most likely to receive “aggressive-approach chemotherapy within 14 days of death.”
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received chemotherapy. Five percent of the 453 patients
in the lowest quintile received chemotherapy near the
end of life, and 12% of the 614 patients in the highest
quintile experienced an aggressive approach to
chemotherapy. Compared to standard chemotherapy,
use of chemotherapy within 14 days of death tended to
be associated with worse survival at 1 year (-53.5 per-
centage points; 95%CI -124.1, 17.2%; P = 0.14) or at 2
years (-35.1 percentage points; 95%CI -76.9, 6.6%; P =
Table 5 Instrumental variable analysis results
Model Patient
population
Variable used for
classification
Variables Lowest
quintile
Second
quintile
Third
quintile
Fourth
quintile
Highest
quintile
Instrumental
variable
estimate
1 All patients
(n = 7,879)
Prevalence of
“chemotherapy”
Number of patients* 1,492 1,388 1,439 1,255 2,139
Chemotherapy recipients,
%
†
30.8 43.4 47.5 49.8 52.3
Aggressive-approach
chemotherapy recipients,
%
†
2.2 3.2 4.2 5.1 4.4
Age at diagnosis, years 73.0 73.3 72.8 73.3 72.8
Female, % 42.2 41.7 42.6 48.3 39.8
non-Hispanic white, % 83.7 85.4 88.1 71.9 82.8
Socioeconomic status,
mean quintile
2.9 2.8 3.0 3.1 3.0
Without comorbidity, % 78.2 73.7 74.5 69.8 69.1
Survival at 1 year after
diagnosis, %
‡
21.7 ±
1.1
23.5 ±
1.1
22.2 ±
1.1
21.7 ±
1.2
23.7 ±
0.9
6.7% (95%CI:
-6.6, 19.9)
Survival at 2 years after
diagnosis, %
‡
5.6 ±
0.6
6.7 ± 0.7 6.1 ±
0.6
4.8 ±
0.6
6.8 ± 0.5 1.7% (95%CI:
-5.9, 9.3)
Hazard Ratio (95%CI)
§ 1.0 0.94
(0.87,
1.01)
0.96
(0.89,
1.03)
1.04
(0.96,
1.12)
0.93
(0.87,
0.99)
2 Chemotherapy
recipients
(n = 3,534)
Prevalence of “aggressive-
approach chemotherapy”
Number of patients
|| 453 136 990 619 614
Chemotherapy recipients,
%
100.0 100.0 100.0 100.0 100.0
Aggressive-approach
chemotherapy recipients,
%
†
4.6 6.6 7.7 10.3 12.1
Age at diagnosis, years 71.7 71.7 71.1 71.7 71.9
Female, % 43.7 44.1 38.6 41.7 43.3
non-Hispanic white, % 89.0 83.8 84.6 86.0 74.8
Socioeconomic status,
mean quintile
3.0 3.3 3.2 3.2 3.2
Without comorbidity, % 73.5 78.7 70.6 79.2 68.2
Survival at 1 year after
diagnosis, %
‡
30.5 ±
2.2
29.4 ±
3.9
26.0 ±
1.4
26.3 ±
1.8
27.9 ±
1.8
-53.5% (95%CI:
-124.1, 17.2)
Survival at 2 years after
diagnosis, %
‡
8.4 ±
1.3
8.1 ± 2.3 7.4 ±
0.8
6.5 ±
1.0
6.2 ± 1.0 -35.1% (95%CI:
-76.9, 6.6)
Hazard Ratio (95%CI)
§ 1.0 1.05
(0.87,
1.28)
1.07
(0.96,
1.20)
1.11
(0.98,
1.25)
1.11
(0.99,
1.26)
Abbreviation: CI, confidence interval; SE, standard error.
* A total of 166 patients who reside in the Health Care Service Areas, where there were five or fewer patients treated with or without chemotherapy, were
excluded.
† P < 0.001
‡ Unadjusted survival derived from Kaplan-Meier method
§ Adjusted hazard ratios and 95% confidence intervals derived from Cox proportional hazards regression model. Patient age, gender, race/ethnicity,
socioeconomic status quintiles, Charlson comorbidity index, and year of death were included in the model.
|| A total of 722 patients who reside in the Health Care Service Areas, where there were five or fewer patients treated with or without aggressive-approach
chemotherapy, were excluded
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receiving chemotherapy near the end of life in geo-
graphic quintiles for IV estimates, however, these differ-
ences were not statistically significant.
Discussion
This study explored the clinical effects of chemotherapy
continued close to the time of death in a large representa-
tive cohort of elderly patients with advanced non-small
cell lung cancer in multiple regions of the United States.
About one tenth (8.5%) of patients who had ever received
chemotherapy were still receiving chemotherapy within 14
days of death; this population experienced no survival ben-
efit as determined by three different statistical approaches.
These patients were also much less likely to receive hos-
pice care or and more likely to receive it for three or fewer
days. These results suggest that patients receiving che-
motherapy within 14 days of death do not benefit from
this aggressive approach to treatment, and they may also
be deprived of good palliative care provided by hospice.
Results from the IVA confirmed that geographic varia-
tions exist in use of chemotherapy, but not in clinical
outcomes. This suggests that physician practice styles or
patient preferences, rather than associated clinical out-
comes, may be driving aggressive treatment decisions
near the end of life.
Several limitations should be noted. The SEER-Medi-
care database is restricted to patients aged 65 or older
and patients insured by an HMO were excluded in this
study, so it is difficult to extrapolate these results to
younger patients and those enrolled in managed care.
However, 60% of cancers occur in patients who are 65
years or older,[34] so Medicare covers most cancer
patients in the United States [35]. As the data were not
collected specifically for research, there may be inaccura-
cies in some of the variables analyzed, such as the Charl-
son comorbidity index, but chemotherapy is a costly
service with strong financial incentives for accurate bill-
ing to Medicare [36,37]. Our data are from patients who
died over a decade ago and so treatment options and
availability have changed. For example, the modern tar-
geted therapy including an introduction of epidermal
growth factor receptor (EGFR) inhibitors [38,39] may
have changed the risk/benefit equation. Still, with respect
to cytotoxic chemotherapy, our data did not detect any
benefit to continuing chemotherapy to near death. Retro-
spective analyses of patient cohorts defined by death have
been criticized because patients’ prognosis may often not
be apparent to treating clinicians and some deaths may
occur despite appropriate efforts to prolong survival [40].
These concerns are mitigated by studying patients who
are known to be terminally ill and who die of their term-
inal illness,[41-43] as we did by focusing on patients initi-
ally diagnosed with metastatic non-small cell lung cancer
who died of their cancer. A systematic review showed
that physicians’ survival predictions in terminally ill can-
cer patients can be inaccurate and generally they are
overoptimistic [44]. Palliation is the only goal of therapy
for patients with metastatic diseases. In such a case, cure
is not an option. If physicians repeatedly give patients
chemotherapy very near death because they simply do
not see death approaching, they may not be delivering
the best care. Similarly, those with a high proportion of
unexplained toxic deaths resulted from continuing che-
motherapy close to death may be delivering poor care.
There may also be a limitation of determining intent of
chemotherapy retrospectively: chemotherapy that hap-
pens to continue to within 14 days of death may not have
been given with the intent of an aggressive approach.
However, this is one of the validated measurements that
we can use with existing administrative data to assess the
intensity of end-of-life cancer care [11,13]. Also, despite
the fact that survival time is part of both the dependent
and explanatory variables, our data showed that the
receipt of aggressive-approach chemotherapy was defined
independent of patients’ life expectancies, which assuages
these limitations. Although observational data do not
permit clear determination of causality, the consistency
of our findings derived from the three sophisticated sta-
tistical approaches with a large sample size is compelling.
Conclusions
We could not detect a benefit in survival from continu-
ing chemotherapy close to death. Furthermore, this
treatment was associated with substantially reduced use
of palliative hospice care. The Health Services Research
Committee of the American Society of Clinical Oncol-
ogy (ASCO) agreed that treatment could still be recom-
mended, even without an improvement in survival, if it
improves the quality of life in the case of metastatic
cancer [45]. Our data suggest that an aggressive
approach to continuing chemotherapy to very near
death likely does not meet this test in that it may result
in no survival benefit, and, in fact, in negative outcomes.
It is imperative that physicians present honest, indivi-
dualized, evidence-based information to patients making
treatment decisions near the end of life about the
expected risks and benefits of chemotherapy.
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